E 49 | The GLP-1 Truth: Why 60% of Users Quit, What Science Really Says, and Who Should Consider Them

Episode Summary12% of Americans have tried GLP-1 drugs like Ozempic and Wegovy, but up to 65% discontinue within the first year. This comprehensive deep-dive examines the latest 2024-2025 research to uncover what's really happening with these medications - from remarkable cardiovascular and brain health benefits to the practical realities of side effects, costs, and discontinuation rates.Key Takeaways✅ GLP-1 drugs provide 20-25% reduction in heart attacks and strokes, independent of weight loss✅ Emerging research shows benefits for brain health, addiction, and kidney protection✅ High discontinuation rates (46-65%) are driven by multiple factors beyond side effects✅ Success depends heavily on proper patient selection and specialist care✅ Cost remains a major barrier with medications exceeding $1,000/monthMAJOR TOPICS COVEREDThe Science Behind GLP-1How natural GLP-1 hormone works in your bodyWhy synthetic versions last longer and work as medicationsDifference between GLP-1 drugs and dual agonists like tirzepatideResearch-Backed BenefitsWeight Loss: 12-22% body weight reduction in clinical trialsCardiovascular Protection: 20-25% reduction in major adverse events (SELECT trial)Kidney Health: First GLP-1 approved for kidney protection (January 2025)Brain Health: Reduced risk of addiction, depression, dementia, and seizuresSleep Apnea: FDA approval for moderate-to-severe casesLiver Health: Benefits for metabolic liver diseaseChallenges & Side EffectsGastrointestinal issues affect 40-70% of users"Ozempic face" and rapid weight loss effectsRare but serious risks: pancreatitis, gastroparesis, kidney injuryCost barriers and insurance coverage gapsSupply chain disruptions and accessibility issuesWho Should Consider These MedicationsClear candidates: Type 2 diabetes, obesity with cardiovascular diseaseEmerging candidates: People with addiction issues, dementia riskImportant considerations: long-term commitment, financial planningWhy specialist care improves success ratesRESEARCH SOURCES CITEDMajor Studies Referenced:Nature Medicine 2025 - Comprehensive analysis of 175 health outcomesJAMA Network 2025 - Discontinuation and reinitiation patternsSELECT Trial - Cardiovascular outcomes in obesityNorthwestern Medicine 2024 - Real-world benefits and risks analysisBMJ 2024 - Comparative effectiveness meta-analysisKey Statistics:12% of US adults have used GLP-1 medications46.5% discontinuation rate (with diabetes) vs 64.8% (without diabetes)$1,000+ monthly cost without insurance40-70% experience gastrointestinal side effectsMEDICATIONS DISCUSSEDGLP-1 Receptor Agonists:Semaglutide (Ozempic, Wegovy)Liraglutide (Victoza, Saxenda)Dulaglutide (Trulicity)Exenatide (Byetta)Dual Agonists:Tirzepatide (Mounjaro, Zepbound)Future Medications:Retatrutide (triple agonist in development)Oral formulations in developmentRESOURCES FOR LISTENERSFind a Specialist:American Association of Clinical Endocrinologists (AACE)Obesity Medicine Association provider directoryCost Resources:Manufacturer patient assistance programsGoodRx and prescription discount programsInsurance coverage advocacy resourcesStay Informed:Follow FDA drug safety communicationsClinical trial databases for emerging researchProfessional medical organization guidelinesIMPORTANT DISCLAIMERSThis episode is for educational purposes only and does not constitute medical adviceAlways consult qualified healthcare providers before starting, stopping, or changing medicationsIndividual results and experiences may vary significantlyCost and insurance coverage information may change frequentlyResearch in this field is rapidly evolvingSubscribe & Review:If this episode added value to your training knowledge, please subscribe and leave a 5-star review! Your feedback helps us reach more fitness enthusiasts who can benefit from quality training information.About Brandon SmitleyInstagram: @bsmitley @team.thirstSubscribe On YouTube!Website: THIRSTgym.comBrandon Smitley is a world renowned strength coach and athlete for over a decade. He and his wife, Adrian, own Terre Haute Intensity Resistance and Sports Training (THIRST) where they work with youth athletes and personal training clients of all ages. He earned his Bachelor’s degree from Purdue University in Health and Fitness, and his Master’s degree from Indiana State University in Physical Education and Coaching. Brandon has been awarded Personal Trainer of the Year Awards from Purdue University and Indiana State University as well is the 2020 Reader's Choice for Best Personal Trainer in Terre Haute, IN and the Wabash Valley.Brandon is a sponsored athlete with Elitefts and NutraBio where as a competitive powerlifter he currently holds the all-time world record squat in the 132 pound weight class, with a 567 pound squat. He also holds a 330 pound bench press, and 510 pound deadlift in that weight class, totaling 1377 pounds, ranking 4th all-time. He provides online coaching and programming around the world, and has personally worked with over 200 athletes in the US, UK, France, Italy, Mexico, Canada, and other countries. Brandon’s been published at Elitefts, Muscle and Performance, and Muscle and Fitness magazine.He holds his Certified Strength and Conditioning Specialist (CSCS), Level One Sports Performance (USAW), Certified Personal Trainer (CPT) certifications, and is educated in PRI for Fitness and Performance.